Physician profile
Sushama Jasti
NPI 1780772277
$3,760.54
in general payments reported to CMS, 2019-2025
48 companies · $794 in 2025
The $794 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,003 · 2020: $239 · 2022: $363 · 2023: $354 · 2024: $1,007 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,055 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,054.89 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $388.51 | 2019-2025 | |
| Janssen Biotech, INC. | $249.26 | 2019-2025 | Darzalex, Tecvayli, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $240.10 | 2019-2025 | Opdivo, Zeposia, Opdualag |
| Merck Sharp & Dohme LLC | $223.05 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $218.17 | 2019-2025 | Monjuvi, Jakafi, Zynyz |
| Novartis Pharmaceuticals Corporation | $187.56 | 2019-2024 | |
| Astellas Pharma US INC | $182.65 | 2019-2025 | Vyloy, Padcev |
| Astrazeneca Pharmaceuticals LP | $149.36 | 2019-2024 | Enhertu, Lynparza |
| Genzyme Corporation | $146.89 | 2019-2025 | |
| Seagen INC. | $142.84 | 2019-2022 | |
| Celgene Corporation | $120.97 | 2022-2025 | Reblozyl, Pomalyst |
| Lilly USA, LLC | $111.11 | 2019-2025 | Jaypirca, Verzenio |
| Amgen INC. | $98.27 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Kite Pharma, INC. | $98.03 | 2024-2025 | Yescarta |
| Genentech USA, INC. | $95.72 | 2019 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sushama Jasti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.